{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T02:23:13Z","timestamp":1785810193785,"version":"3.56.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T00:00:00Z","timestamp":1610150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T00:00:00Z","timestamp":1610150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s40262-020-00972-1","type":"journal-article","created":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T15:06:18Z","timestamp":1610204778000},"page":"649-654","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic Analysis"],"prefix":"10.1007","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1991-0552","authenticated-orcid":false,"given":"Nikki","family":"de Rouw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene J.","family":"Boosman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alwin D. R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luuk B.","family":"Hilbrands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elin M.","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hieronymus J.","family":"Derijks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel M.","family":"van den Heuvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"ter Heine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,9]]},"reference":[{"issue":"Suppl 4","key":"972_CR1","doi-asserted-by":"publisher","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","volume":"29","author":"D Planchard","year":"2018","unstructured":"Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S, Committee EG. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv192\u2013237.","journal-title":"Ann Oncol."},{"issue":"Suppl 5","key":"972_CR2","doi-asserted-by":"publisher","first-page":"v31","DOI":"10.1093\/annonc\/mdv199","volume":"26","author":"P Baas","year":"2015","unstructured":"Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters S, Committee EG. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v31\u20139.","journal-title":"Ann Oncol."},{"issue":"Suppl 5","key":"972_CR3","doi-asserted-by":"publisher","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","volume":"26","author":"N Girard","year":"2015","unstructured":"Girard N, Ruffini E, Marx A, Faivre-Finn C, Peters S. Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v40\u201355.","journal-title":"Ann Oncol"},{"issue":"5","key":"972_CR4","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s002800050992","volume":"44","author":"DA Rinaldi","year":"1999","unstructured":"Rinaldi DA, Kuhn JG, Burris HA, Dorr FA, Rodriguez G, Eckhardt SG, et al. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol. 1999;44(5):372\u201380.","journal-title":"Cancer Chemother Pharmacol."},{"issue":"4","key":"972_CR5","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1200\/JCO.2004.00.9720","volume":"24","author":"AC Mita","year":"2006","unstructured":"Mita AC, Sweeney CJ, Baker SD, Goetz A, Hammond LA, Patnaik A, et al. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol. 2006;24(4):552\u201362.","journal-title":"J Clin Oncol."},{"issue":"1","key":"972_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00408-008-9123-5","volume":"187","author":"V Launay-Vacher","year":"2009","unstructured":"Launay-Vacher V, Etessami R, Janus N, Spano JP, Ray-Coquard I, Oudard S, Gligorov J, Pourrat X, Beuzeboc P, Deray G, Morere JF, Renal Insufficiency Anticancer Medications Study G. Lung cancer and renal insufficiency: prevalence and anticancer drug issues. Lung. 2009;187(1):69\u201374.","journal-title":"Lung"},{"issue":"4","key":"972_CR7","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00280-005-0036-1","volume":"57","author":"JE Latz","year":"2006","unstructured":"Latz JE, Chaudhary A, Ghosh A, Johnson RD. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. Cancer Chemother Pharmacol. 2006;57(4):401\u201311.","journal-title":"Cancer Chemother Pharmacol."},{"key":"972_CR8","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ejca.2019.08.012","volume":"121","author":"S Visser","year":"2019","unstructured":"Visser S, Koolen SLW, de Bruijn P, Belderbos HNA, Cornelissen R, Mathijssen RHJ, et al. Pemetrexed exposure predicts toxicity in advanced non-small-cell lung cancer: A PROSPECTIVE cohort study. Eur J Cancer. 2019;121:64\u201373.","journal-title":"Eur J Cancer."},{"issue":"9","key":"972_CR9","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/jcph.1417","volume":"59","author":"M Srinivasan","year":"2019","unstructured":"Srinivasan M, Chaturvedula A, Fossler MJ, Patil A, Gota V, Prabhash K. Population pharmacokinetics of pemetrexed in adult non-small cell lung cancer in Indian patients. J Clin Pharmacol. 2019;59(9):1216\u201324.","journal-title":"J Clin Pharmacol."},{"key":"972_CR10","unstructured":"Clinical Study Data Request. https:\/\/www.clinicalstudydatarequest.com\/Posting.aspx?ID=19619&GroupID=SUMMARIES. Accessed 20 Nov 19."},{"issue":"1","key":"972_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31\u201341.","journal-title":"Nephron."},{"issue":"4","key":"972_CR12","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1373\/clinchem.2006.077180","volume":"53","author":"AS Levey","year":"2007","unstructured":"Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F, Chronic Kidney Disease Epidemiology C. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53(4):766\u201372.","journal-title":"Clin Chem."},{"issue":"9","key":"972_CR13","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, Chronic Kidney Disease Epidemiology Collaboration. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med."},{"key":"972_CR14","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1038\/psp.2013.26","volume":"2","author":"W Byon","year":"2013","unstructured":"Byon W, Smith MK, Chan P, Tortorici MA, Riley S, Dai H, et al. Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance. CPT Pharmacometr Syst Pharmacol. 2013;2:e51.","journal-title":"CPT Pharmacometr Syst Pharmacol."},{"key":"972_CR15","unstructured":"Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey (NHANES) [Nov 2019]. https:\/\/www.cdc.gov\/nchs\/nhanes\/index.htm. Accessed 6 Nov 2019."},{"issue":"1","key":"972_CR16","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1158\/1078-0432.CCR-08-0791","volume":"15","author":"JE Latz","year":"2009","unstructured":"Latz JE, Schneck KL, Nakagawa K, Miller MA, Takimoto CH. Population pharmacokinetic\/pharmacodynamic analyses of pemetrexed and neutropenia: effect of vitamin supplementation and differences between Japanese and Western patients. Clin Cancer Res. 2009;15(1):346\u201354.","journal-title":"Clin Cancer Res."},{"issue":"10","key":"972_CR17","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1158\/1078-0432.CCR-09-3324","volume":"16","author":"NJ Dickgreber","year":"2010","unstructured":"Dickgreber NJ, Sorensen JB, Paz-Ares LG, Kjestrup Schytte T, Latz JE, Schneck KB, et al. Pemetrexed safety and pharmacokinetics in patients with third-space fluid. Clin Cancer Res. 2010;16(10):2872\u201380.","journal-title":"Clin Cancer Res."},{"issue":"4","key":"972_CR18","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s00280-005-0077-5","volume":"57","author":"JE Latz","year":"2006","unstructured":"Latz JE, Karlsson MO, Rusthoven JJ, Ghosh A, Johnson RD. A semimechanistic-physiologic population pharmacokinetic\/pharmacodynamic model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol. 2006;57(4):412\u201326.","journal-title":"Cancer Chemother Pharmacol."},{"issue":"4","key":"972_CR19","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00280-005-0035-2","volume":"57","author":"JE Latz","year":"2006","unstructured":"Latz JE, Rusthoven JJ, Karlsson MO, Ghosh A, Johnson RD. Clinical application of a semimechanistic-physiologic population PK\/PD model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol. 2006;57(4):427\u201335.","journal-title":"Cancer Chemother Pharmacol."},{"issue":"April","key":"972_CR20","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.lungcan.2019.01.018","volume":"130","author":"N de Rouw","year":"2019","unstructured":"de Rouw N, Croes S, Posthuma R, Agterhuis DE, Schoenmaekers JJAO, Derijks HJ, et al. Pharmacokinetically-guided dosing of pemetrexed in a patient with renal impairment and a patient requiring hemodialysis. Lung Cancer. 2019;130(April):156\u20138.","journal-title":"Lung Cancer."},{"issue":"11","key":"972_CR21","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","volume":"7","author":"AH Calvert","year":"1989","unstructured":"Calvert AH, Newell DR, Gumbrell LA, O\u2019Reilly S, Burnell M, Boxall FE, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7(11):1748\u201356.","journal-title":"J Clin Oncol."},{"issue":"8","key":"972_CR22","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1172\/JCI107362","volume":"52","author":"BA Chabner","year":"1973","unstructured":"Chabner BA, Young RC. Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. J Clin Invest. 1973;52(8):1804\u201311.","journal-title":"J Clin Invest."},{"issue":"3","key":"972_CR23","first-page":"605","volume":"4","author":"AC McDonald","year":"1998","unstructured":"McDonald AC, Vasey PA, Adams L, Walling J, Woodworth JR, Abrahams T, et al. A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin Cancer Res. 1998;4(3):605\u201310.","journal-title":"Clin Cancer Res."},{"issue":"1","key":"972_CR24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I","volume":"41","author":"WA Bleyer","year":"1978","unstructured":"Bleyer WA. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer. 1978;41(1):36\u201351.","journal-title":"Cancer"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00972-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-020-00972-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00972-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T07:55:56Z","timestamp":1697529356000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-020-00972-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,9]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["972"],"URL":"https:\/\/doi.org\/10.1007\/s40262-020-00972-1","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,9]]},"assertion":[{"value":"28 November 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Nikki de Rouw, Rene J. Boosman, Alwin D.R. Huitema, Luuk B. Hilbrands, Elin M. Svensson, Hieronymus J. Derijks, Michel M. van den Heuvel, David M. Burger, and Rob ter Heine have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Manufacturer\u2019s consent for publication.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Supplementary file.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Study concepts: NR, RJB, ADRH, LBH, EMS, HJD, MMH, DMB, RH. Study design: NR, RJB, ADRH, RH. Data acquisition and control: NR, RJB, RH. Data analysis and interpretation and statistical analysis: NR, RH. Manuscript preparations: NR, RH. Manuscript editing and revisions: NR, RJB, ADRH, LBH, EMS, HJD, MMH, DMB, RH.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}